AEterna Zentaris Inc. (AEZS)

[valeriana]

Here's my thinking...

An unexpected positive PR on Sept 28th, with actual clinical data meeting primary endpoints on a separate indication (which is great catalyst), failed to hold this stock above 0.10, and it's back stalled and flirting with 8's again.

If that trial news couldn't help out AEZS, how could the DSMB just saying "yes, looks good, continue the study" provide any bigger catalyst?

Don't blame the warrants... even if converted, I doubt this small DSMB news will provide any massive immediate upswing. Maybe 0.20's tops this year. Only way you'll probably see a huge spike is with: unexpected partnership (maybe), Zoptec being recommended for immediate approval (unlikely), or another PR on a separate un-related product.

Don't get me wrong.. when Zoptec study is completed late 2016 and finally submitted and OK'ed for approval, this will be a multiple dollar stock. But until then... ehh...

Again, imo.